Inhibrx Biosciences
Inhibrx Biosciences' revenue rose 550.0% to $1 million in fiscal 2025. Its operating margin was −10,386.5%, up from −165,724.0% a year earlier. Free cash flow was −$130 million. The diluted share count rose 3.4%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Inhibrx Biosciences does
Inhibrx Biosciences is a clinical-stage drug company, which means it is testing experimental medicines in people and has none approved for sale. It builds protein-based drugs, called biologics, with its own protein engineering technology. Its drugs are built to attach to a target on cells in several places at once, in a way it believes is best for each target.
It has two drug candidates in human trials, both for cancer. Ozekibart (INBRX-109) acts on a cell receptor called DR5 and is being tested in chondrosarcoma, Ewing sarcoma, colorectal cancer and certain other solid tumors. INBRX-106 acts on a receptor called OX40 and is being tested in non-small cell lung cancer and head and neck squamous cell carcinoma. It also has a discovery pipeline of earlier programs.
The company was formed in May 2024, when the former Inhibrx, Inc. spun off these programs as Sanofi bought that company and took over its INBRX-101 therapy for a rare lung and liver disease. Inhibrx Biosciences has never earned revenue from product sales and has lost money since it started. It pays for its work by raising money from investors and through lending, licensing and collaboration deals.
Its biggest risks, as it describes them
- Losses since it began and a limited operating history, with no revenue from product sales so far.
- Candidates that may not prove safe or effective enough to win marketing approval.
- Its protein engineering approach is novel and unproven, so cost, timing and success are hard to predict.
- Needing more money, which could dilute shareholders or limit its operations.
- Having only two drug candidates in human trials, so a setback for one would weigh heavily.
Income statement
Inhibrx Biosciences lost money in fiscal 2025: a net loss of $140 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY23 | FY24 | FY25 |
|---|---|---|---|
| Cash and short-term investments | 278 | 153 | 124 |
| Debt incl. finance leases | 207 | 0 | 101 |
| Net debt (negative means net cash) | −71 | −153 | −24 |
| Net debt to EBITDA | — | — | — |
| Debt to equity | 4.8x | 0.0x | 12.6x |
| Interest coverage | −6.9x | −24.6x | −11.1x |
| Current ratio | 5.2x | 3.9x | 3.9x |
| Quick ratio | 5.2x | 3.9x | 3.9x |
Cash flow
Projections
Project Inhibrx Biosciences' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
No officer, director or 10% owner of Inhibrx Biosciences reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY24 | FY25 |
|---|---|---|
| Piotroski F-score | — | 2 of 8 |
| Rule of 40 | −98,591.9% | −9,436.5% |
| Altman Z'' | −6.92 | −7.18 |
| Accruals ratio | 770.3% | −6.3% |
The nine F-score tests
| Test | FY24 | FY25 |
|---|---|---|
| Net income is positive | Pass | Fail |
| Cash from operations is positive | Fail | Fail |
| Return on assets rose | — | Fail |
| Cash from operations exceeds net income | Fail | Pass |
| Debt fell relative to assets | — | Fail |
| Current ratio rose | Fail | Fail |
| Share count didn't rise | Fail | Fail |
| Gross margin rose | — | — |
| Revenue rose relative to assets | — | Pass |
| F-score | — | 2 of 8 |
Compare
Put Inhibrx Biosciences side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Inhibrx Biosciences | FY25 | 550.0% | −10,386.5% | −9,986.5% | — | — | 2 | |
| Z Squared | FY25 | — | −956.9% | — | — | — | — | Compare |
| Celldex Therapeutics | FY25 | −78.0% | −18,599.8% | −13,829.1% | — | — | — | Compare |
| Shattuck Labs | FY25 | −82.5% | −5,150.8% | −3,995.3% | — | — | — | Compare |
| Absci | FY25 | −38.2% | −4,297.0% | −3,358.3% | −162.8% | — | 3 | Compare |
3 years of figures
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Income statement | |||
| Revenue | 2 | 0 | 1 |
| Revenue growth | — | −88.9% | 550.0% |
| Gross profit | — | — | — |
| Research and development | 192 | 204 | 113 |
| Operating income | −219 | −331 | −135 |
| Net income | −241 | 1,688 | −140 |
| Diluted EPS (US$) | −20.48 | 112.62 | −9.04 |
| Diluted shares (millions) | 12 | 15 | 16 |
| Cash flow | |||
| Cash from operations | −193 | −194 | −130 |
| Capital expenditure | 5 | 3 | 0 |
| Free cash flow | −198 | −197 | −130 |
| Dividends paid | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 |
| Stock-based compensation | 25 | 58 | 11 |
| Balance sheet at fiscal year end | |||
| Cash and short-term investments | 278 | 153 | 124 |
| Debt incl. finance leases | 207 | 0 | 101 |
| Total assets | 308 | 181 | 146 |
| Total liabilities | 264 | 47 | 138 |
| Shareholders' equity | 44 | 134 | 8 |
| Margins and ratios | |||
| Gross margin | — | — | — |
| Operating margin | −12,178.9% | −165,724.0% | −10,386.5% |
| Net margin | −13,408.9% | 843,786.0% | −10,773.5% |
| Free cash flow margin | −10,994.6% | −98,503.0% | −9,986.5% |
| Rule of 40 (growth + FCF margin) | — | −98,591.9% | −9,436.5% |
| Return on capital | — | — | — |
| Return on equity | — | 1,905.9% | −197.8% |
| Return on assets | — | 690.7% | −85.6% |
| Net debt to EBITDA | — | — | — |